Comparison of Rifabutin- and Levofloxacin-based Third-line Rescue Therapies for Helicobacter pylori / 대한소화기학회지
The Korean Journal of Gastroenterology
;
: 401-406, 2012.
Article
in Korean
| WPRIM
| ID: wpr-155648
ABSTRACT
BACKGROUND/AIMS:
There is increasing need for third-line therapy of Helicobacter pylori due to increasing level of antibiotics resistance. The aim of this study was to compare rifabutin and levofloxacin rescue regimens in patients with first- and second-line Helicobacter pylori eradication failures.METHODS:
Patients, in whom a first treatment with proton pump inhibitor-clarithromycin-amoxicillin and a second trial with proton pump inhibitor-bismuth-tetracycline-metronidazole had failed, received treatment with either rifabutin or levofloxacin, plus amoxicillin (1 g twice daily) and standard dose proton pump inhibitor. Eradication rates were confirmed with 13C-urea breath test or rapid urease test 4 weeks after the cessation of therapy.RESULTS:
Eradication rates were 71.4% in the rifabutin group, and 57.1% in the levofloxacin group, respectively. Although there was no significant difference in Helicobacter pylori eradication rates between two groups (p=0.656), rifabutin based regimen showed relatively higher eradication rate.CONCLUSIONS:
Helicobacter pylori eradication rates of rifabutin- or levofloxacin-based triple therapy could not achieve enough eradication rate. Further studies would be needed on combination of levofloxacin and rifabutin-based regimen or culture based treatment.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Breath Tests
/
Ofloxacin
/
Helicobacter pylori
/
Helicobacter Infections
/
Salvage Therapy
/
Rifabutin
/
Drug Resistance, Bacterial
/
Drug Therapy, Combination
/
Proton Pump Inhibitors
/
Amoxicillin
Limits:
Adult
/
Aged
/
Aged80
/
Female
/
Humans
/
Male
Language:
Korean
Journal:
The Korean Journal of Gastroenterology
Year:
2012
Type:
Article
Similar
MEDLINE
...
LILACS
LIS